The Stock Exchange of Hong Kong Limited (the Exchange) has concluded its consultation on a listing regime for emerging and innovative companies and finalised the related Hong Kong Listing Rules and guidance letters.
From 30 April 2018, biotech companies that are pre-revenue are permitted to list under a new chapter (the Biotech Chapter) in the Main Board Listing Rules (the Listing Rules).
